Douglas Carr Sells Shares of Century Therapeutics

On June 12, 2026, Douglas Carr, Senior Vice President of Finance & Operations at Century Therapeutics, Inc. (NasdaqCM: IPSC), sold 1,654 shares of the company. The transaction was valued at approximately $3,688, with an average selling price of $2.23 per share. This sale was not part of a pre-arranged trading plan.

Insider Buying and Selling at Century Therapeutics, Inc.

Several insiders at Century Therapeutics have been active in the market recently. On June 12, 2026, Gregory Russotti, Chief Technology and Manufacturing Officer, sold 2,584 shares at $2.23 each. Earlier, on June 11, 2026, Brent Pfeiffenberger, President and CEO, sold 13,849 shares at $2.24, and Chad Cowan, Chief Scientific Officer, sold 358 shares at the same price. Additionally, Han Myung Lee and Daphne Quimi each bought 74,000 shares on June 11, 2026.

Other Institutional Activity in Century Therapeutics

Several institutional investors have shown interest in Century Therapeutics. Versant Venture Management, LLC increased its stake significantly, adding 24,332,218 shares, bringing its total to 24,332,218 shares valued at about $54.9 million. TCG Crossover Management, LLC also added 17,754,430 shares, now holding the same amount worth approximately $39.0 million. RA Capital Management, L.P. and Deep Track Capital, LP both increased their holdings by 17,754,430 and 9,487,745 shares, respectively, with their positions valued at $40.1 million and $21.4 million. RTW Investments, LP and Venrock Adviser, LLC each added 8,695,652 shares, with holdings valued at about $19.7 million.

Century Therapeutics, Inc. Stock Up 13.6%

Shares of Century Therapeutics (NasdaqCM: IPSC) are currently trading around $2.25. The company has a market capitalization of approximately $405.8 million. With a beta of 1.566, the stock has shown some volatility. Its 52-week trading range is between $0.43 and $3.04. The 50-day moving average is $2.28, while the 200-day moving average is $1.48. The company maintains a strong financial position with a current ratio of 10.25 and a quick ratio of 10.04, though it has a debt-to-equity ratio of 18.14.

Analysts Set New Price Targets

Analysts have been keeping a close eye on Century Therapeutics. On May 27, 2026, Mizuho initiated coverage with a 'buy' rating and set an $8.00 price target. HC Wainwright & Co. maintained its 'buy' rating with a $5.00 target on April 21, 2026. Piper Sandler also maintained a 'buy' rating, setting a $4.00 target on January 20, 2026. The consensus among analysts is a 'buy' rating, with a mean price target of $4.75 based on four analyst opinions.

About Century Therapeutics

Century Therapeutics, Inc. is a biotechnology company based in Philadelphia, Pennsylvania. It focuses on developing allogeneic cell therapies for treating solid tumors, hematological malignancies, and autoimmune diseases. The company's lead product candidate is CNTY-813, targeted for type 1 diabetes treatment. Other developments include CNTY-308 for B-cell-mediated autoimmune diseases and CNTY-101 for CD19-related conditions. Founded in 2018, the company is led by CEO Dr. Brent Pfeiffenberger and employs about 78 people.

Bottom Line

This insider activity at Century Therapeutics is a reminder for investors to stay informed about changes within companies they follow. With a strong institutional interest and positive analyst sentiment, Century Therapeutics continues to be a company to watch in the biotechnology sector. Remember, insider transactions like these are backward-looking and may not reflect current positions.